SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

GTBP

GT Biopharma, Inc.
MIXED
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The widened net loss is not reflective of operational deterioration but a non-cash accounting item. The improved cash runway and upcoming clinical catalysts (GTB-5550 initiation, Q3 2026 data update) may support investor sentiment, but the small market cap ($13M) and history of losses suggest high risk. Monitor for future funding needs and clinical data.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.4670
T+0 close · Mar 2, 2026 · via day close
Latest settled
−16.06%
T+60 · $0.3920
Vs SPY
−25.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $0.4670entry
  2. T+1 · 9mo ago +0.64%α +1.56% · $0.4700
  3. T+5 · 8mo ago −10.71%α −9.50% · $0.4170
  4. T+20 · 8mo ago −11.35%α −3.41% · $0.4140
  5. T+60 · 6mo ago −16.06%α −25.39% · $0.3920
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GT Biopharma reported its 2025 financial results, showing reduced R&D and operating losses but a sharply higher net loss due to a $15.2M non-cash charge tied to preferred stock valuation. The company has $7M in cash as of year-end 2025, with a proforma balance of $9M in January 2026, funding operations through Q4 2026. Clinical progress includes ongoing GTB-3650 enrollment and FDA clearance for GTB-5550, with a trial expected to start mid-2026.

Key Facts

  • Cash and cash equivalents: $7M as of December 31, 2025; unaudited proforma cash of $9M as of January 31, 2026
  • Net loss: $28.4M in 2025 vs. $13.2M in 2024, driven by a $15.2M non-cash expense from preferred stock valuation
  • R&D expenses decreased to $3.5M from $5.8M due to lower production costs
  • Loss from operations improved to $12.4M from $14.4M
  • SG&A expenses flat at ~$8.5M
  • GTB-3650 Phase 1 trial ongoing, with Cohort 5 (25 µg/kg/day) expected to start in Q2 2026; next data update expected Q3 2026
  • FDA cleared IND for GTB-5550 in January 2026; Phase 1 basket trial expected to initiate mid-2026

Financial Impact

Net loss widened by $15.2M due to non-cash charge; operating loss improved by $2M. Cash runway extended to Q4 2026 with $9M proforma balance.

net losscash positionR&D expensesoperating loss

Risk Factors

  • Company faces going concern risk as noted in forward-looking statements
  • High net loss despite lower operating expenses due to non-cash items may concern investors
  • Need for future capital raises could lead to dilution
  • Clinical trial delays could impact timeline and funding runway

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247203

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026